Skip to main content

Table 4 Incidence of signs, symptoms, and events in the past 12 months

From: Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

Sign, symptom, or event, n (%)

Currently using HU therapy (n = 1080)

Discontinued HU therapy (n = 229)

Fatigue or tiredness

304 (28.1)

74 (32.3)

Splenomegaly

267 (24.7)

60 (26.2)

Plethora

138 (12.8)

27 (11.8)

Dizziness

112 (10.4)

41 (17.9)*

Headache

108 (10.0)

23 (10.0)

Abdominal discomfort/pain

106 (9.8)

39 (17.0)*

Hepatomegaly

103 (9.5)

27 (11.8)

Pruritus

96 (8.9)

23 (10.0)

Feeling of fullness

89 (8.2)

28 (12.2)

Thrombotic eventsa

64 (5.9)

11 (4.8)

Cardiovascular problems

52 (4.8)

14 (6.1)

Bone pain

43 (4.0)

16 (7.0)*

Anemia

28 (2.6)

13 (5.7)*

Thrombophlebitis

24 (2.2)

3 (1.3)

Thrombosis

22 (2.0)

2 (0.9)

Neutropenia

21 (1.9)

3 (1.3)

Thrombocytopenia

14 (1.3)

4 (1.8)

Stroke/TIA

18 (1.7)

5 (2.2)

Pulmonary embolism

7 (0.6)

1 (0.4)

Cancer

5 (0.5)

0

Elevation in blasts

2 (2.1)

4 (1.8)

Unknown

21 (1.9)

12 (5.2)*

No new symptoms

471 (43.6)

91 (39.7)

  1. HU hydroxyurea, TIA transient ischemic attack
  2. Values in italics identify signs, symptoms, or events that were significantly (P < 0.05) different between patients currently using HU therapy and those who discontinued HU therapy
  3. * P0.05
  4. aIncludes all patients who experienced pulmonary embolism, stroke/TIA, thrombophlebitis, and/or thrombosis; patients may have experienced more than 1 thrombotic event